Anlotinib (AL3818) is a novel small molecule multi-targeted tyrosine kinase inhibitor, which targets vascular endothelial growth factor receptor (VEGFR), platelet derived growth factor receptor (PDGFR) and fibroblast growth factor receptor (FGFR) to comprehensively block tumor angiogenesis (Shen et al., 2018). The gene discussed is KDR; the disease is neoplasm.